Trimetazidine (Trimetazidine)

Has antihypoxic effect. Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is caused by an increase in the energy potential, activation of oxidative decarboxylation, and optimization of oxygen consumption (enhancement of aerobic glycolysis and blockade of fatty acid oxidation). Supports contractility of the myocardium prevents intracellular depletion of ATP and creatine phosphate. In conditions of acidosis it normalizes the functioning of ion channels of membranes, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content, due to myocardial ischemia. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in zone of ischemia, normalizes the duration of action potential and activity of creatine phosphokinase, reduces the severity of ischemic myocardial damage.

When angina pectoris reduces the frequency of attacks (helps reduce nitrate intake), after 2 weeks of treatment provides increased tolerance to exercise, reduces sudden fluctuations in blood pressure (BP). Improves hearing and results of vestibular samples in patients, reduces dizziness and tinnitus. In vascular pathology, the eye restores the functional activity of the retina.